Journal of Immunology Research

The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections


Publishing date
30 May 2014
Status
Published
Submission deadline
10 Jan 2014

Lead Editor

1Laboratory of Oncology, Istituto Giannina Gaslini, Genoa, Italy

2Neuroradiology Unit, Department of Neurosciences and Rehabilitation, Azienda Ospedaliera-Universitaria, Arcispedale Sant’Anna, Ferrara, Italy

3Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Ferrara, Italy

4Laboratoire d’Immunologie de la TransplantationCEA-DSV-IMETI-SRHI, Hôpital Saint-Louis, Paris, France


The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections

Description

HLA-class Ib family includes HLA-E, -F, -G, and -H molecules that, in contrast with high polymorphic HLA-class Ia molecules (HLA-A, -B, and -C), display a limited polymorphism, with a small number of alleles encoding limited functional proteins. Similar to HLA-class Ia molecules, HLA-class Ib molecules bind peptides generated from cytosolic antigens and present them to CD8+ T lymphocytes, but their main function is the regulation of immune responses, both in physiological and pathological conditions.

HLA-G is the best characterized HLA-Ib molecule. It is expressed on fetal cytotrophoblast cells during pregnancy and abrogates maternal NK cell cytotoxicity against fetal tissues. However, HLA-G is also expressed (or released as soluble molecule) by different human tumors. HLA-G interacts with specific receptors on T and B lymphocytes, NK cells, and antigen presenting cells, inhibiting their function.

HLA-E is virtually expressed by all nucleated cells and binds peptides derived from HLA-class I molecules leader sequence. In physiological conditions, it interacts with CD94/NKG2A inhibitory receptor on NK cells, inhibiting their cytotoxicity against cells displaying normal HLA-class I molecules expression. When such molecules are downregulated (i.e., transformed or infected cells), HLA-class I-derived peptides are lower, and subsequently HLA-E expression is dampened, allowing NK cells to lyse these cells. However, different transformed cells upregulate HLA-E expression to avoid NK cell-mediated lysis.

Limited information is available regarding HLA-F function. This molecule acts as chaperone for the β2-microglobulin-free heavy chain of other HLA-class I molecules, and it is expressed on the surface of activated lymphocytes. So far, no functional HLA-H molecules encoded by HLA-H genes have been characterized.We are interested in articles that explore novel aspects of HLA-Ib molecules function. Potential topics include, but are not limited to:

  • Expression and function of HLA-Ib molecules in pathological conditions that have not yet been investigated, including tumors, infections (virus, bacteria, and other parasites), and autoimmune/inflammatory diseases
  • Interactions between HLA-G, -E, and -F in pathological conditions
  • Novel mechanism of HLA-Ib molecule-mediated immune regulation
  • Possible effects of HLA-Ib molecules on cells that are crucial in pathological settings (i.e., endothelial cells during angiogenesis)
  • Presence of soluble HLA-Ib molecules in biological fluids during disease and their clinical relevance
  • HLA-Ib molecules expression and/or secretion in novel immune-regulatory cell subsets
  • Potential extraimmunological roles of HLA-Ib molecules

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jir/hla/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 231618
  • - Editorial

The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections

Fabio Morandi | Enrico Fainardi | ... | Nathalie Rouas-Freiss
  • Special Issue
  • - Volume 2014
  • - Article ID 274584
  • - Research Article

HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

M. J. Rutten | F. Dijk | ... | E. S. Jordanova
  • Special Issue
  • - Volume 2014
  • - Article ID 230346
  • - Research Article

Osteodifferentiated Mesenchymal Stem Cells from Bone Marrow and Adipose Tissue Express HLA-G and Display Immunomodulatory Properties in HLA-Mismatched Settings: Implications in Bone Repair Therapy

Florent Montespan | Frédéric Deschaseaux | ... | Nathalie Rouas-Freiss
  • Special Issue
  • - Volume 2014
  • - Article ID 159247
  • - Research Article

Differential Transcript Profiles of MHC Class Ib(Qa-1, Qa-2, and Qa-10) and Aire Genes during the Ontogeny of Thymus and Other Tissues

Breno Luiz Melo-Lima | Adriane Feijó Evangelista | ... | Eduardo Antonio Donadi
  • Special Issue
  • - Volume 2014
  • - Article ID 298569
  • - Review Article

Immunomodulatory Properties of HLA-G in Infectious Diseases

Laurence Amiot | Nicolas Vu | Michel Samson
  • Special Issue
  • - Volume 2014
  • - Article ID 657625
  • - Review Article

Some Basic Aspects of HLA-G Biology

Estibaliz Alegre | Roberta Rizzo | ... | Alvaro González
  • Special Issue
  • - Volume 2014
  • - Article ID 153981
  • - Research Article

HLA-G Dimers in the Prolongation of Kidney Allograft Survival

Maureen Ezeakile | Vera Portik-Dobos | ... | Anatolij Horuzsko
  • Special Issue
  • - Volume 2014
  • - Article ID 734068
  • - Review Article

Transcriptional and Posttranscriptional Regulations of the HLA-G Gene

Erick C. Castelli | Luciana C. Veiga-Castelli | ... | Eduardo A. Donadi
  • Special Issue
  • - Volume 2014
  • - Article ID 636292
  • - Research Article

HLA-G Expression on Blasts and Tolerogenic Cells in Patients Affected by Acute Myeloid Leukemia

Grazia Locafaro | Giada Amodio | ... | Silvia Gregori
  • Special Issue
  • - Volume 2014
  • - Article ID 938561
  • - Research Article

IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN- Release by Autologous NK Cells

Fabio Morandi | Irma Airoldi | Vito Pistoia
Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision64 days
Acceptance to publication30 days
CiteScore3.330
Impact Factor3.404
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.